BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

  March 25, 2025

   · 

  2 min read
• Press Releases

  Cognito Therapeutics to Present New Data on Spectris’™ Impact on Brain Structure in Alzheimer’s Disease at AD/PD 2025

  March 25, 2025

   · 

  2 min read
• Press Releases

  Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

  March 25, 2025

   · 

  1 min read
• 

  Immunology and inflammation

  Hillstar Bio Nets $67M Series A to Advance Autoimmune and Arthritis Pipeline

  Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

  March 25, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• Press Releases

  MAIA Biotechnology Announces Poster Presentation at ESMO’s European Lung Cancer Congress 2025

  March 25, 2025

   · 

  5 min read
• Press Releases

  Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction

  March 25, 2025

   · 

  2 min read
• 

  Vaccines

  GSK Builds on Real-World Experiment to Study Shingrix’s Impact on Dementia

  The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” experiment to determine whether 65- and 66-year-olds who received GSK’s shingles vaccine Shingrix have reduced dementia risk.

  March 25, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Layoffs

  Alector Cuts Staff Again, This Time Laying Off 13% of Workforce

  As part of cost-cutting efforts, Alector is letting go of about 25 people as it focuses on advancing its preclinical and research pipeline. Alector is also continuing clinical-stage work on programs for frontotemporal dementia and Alzheimer’s disease.

  March 25, 2025

   · 

  2 min read

   · 

  Angela Gabriel
• Press Releases

  Porosome Therapeutics Unveils Groundbreaking Discovery in Alzheimer’s Disease Research and Treatment

  March 25, 2025

   · 

  5 min read
• 

  Alzheimer’s disease

  Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam

  After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.

  March 25, 2025

   · 

  1 min read

   · 

  Annalee Armstrong